Program of Midostaurin by Novartis

Novartis has set up a compassionate use program of Midostaurin for FLT3+ AML patients eligible for standard induction and consolidation chemotherapy.

This CUP has been approved by the Belgian authorities. More information can be found on www.famhp.be/en/human_use/medicines/medicines/research_development/compassionate_use_medical_need/rydaptr

 

For more information, please contact Belgium.oncology@novartis.com